Cefaclor: clinical and bacteriological evaluation in 45 cases.
This report deals with studies of the effectiveness, tolerance and toxicity of cefaclor in the treatment of 45 patients with urinary tract infections (40 cases) and pneumonia (5 cases) caused by susceptible pathogens. Cefaclor was administered orally in a dosage of 1 to 3 g per day for 7 to 11 days. Clinical and laboratory examinations were performed before, during, at the end of treatment, and 4 weeks later in cases of urinary infection. All 5 patients with pneumonia and bronchopneumonia were cured. Clinical and bacteriological cures were obtained in 28 (70%) of the 40 cases of urinary tract infections. Identification and typing of microorganisms, disk sensitivity tests, minimal inhibitory concentrations and cefaclor blood levels also were determined.
D000328:Adult; D000368:Aged; D002433:Cefaclor / Q000494:pharmacology / Q000627:therapeutic use*; D002506:Cephalexin / Q000031:analogs & derivatives*; D004755:Enterobacteriaceae / Q000187:drug effects / Q000302:isolation & purification; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification; D013296:Streptococcus pneumoniae / Q000187:drug effects / Q000302:isolation & purification; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D002433:Cefaclor; D002506:Cephalexin